Blog
RSS FeedPosted by Michael Wonder on 21 Mar 2019
NICE terminates yet another assessment of a cancer medicine
20 March 2019 - This time it is pembrolizumab (Keytruda). ...
Posted by Michael Wonder on 21 Mar 2019
Institute for Clinical and Economic Review releases draft evidence report on esketamine for treatment-resistant depression
21 March 2019 - Public comment period now open until 17 April 2019; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 19 Mar 2019
NICE wants to stop saying ‘no’ – but needs pharma’s co-operation
18 March 2019 - Suggests Orkambi row has undermined confidence in NICE process. ...
Posted by Michael Wonder on 19 Mar 2019
Institute for Clinical and Economic Review appoints new members to each of its three independent evidence appraisal councils
18 March 2019 - New members bring expertise in broad range of perspectives, including patient advocacy, health policy, economics, and clinical ...
Posted by Michael Wonder on 18 Mar 2019
NICE celebrates its 20th anniversary
18 March 2019 - Organisation was founded in April 1999 to improve outcome for health service users ...
Posted by Michael Wonder on 17 Mar 2019
Toward a strategy to involve patients in health technology assessment in Spain
14 March 2019 - The aim of this study was to develop a feasible and effective strategy to involve patients in ...
Posted by Michael Wonder on 15 Mar 2019
PBAC Public Summary Documents - November 2018 meeting (rejections and deferrals)
15 March 2019 - The Public Summary Documents (first time rejections and deferrals) from the November 2018 PBAC meeting are now ...
Posted by Michael Wonder on 14 Mar 2019
Institute for Clinical and Economic Review releases draft evidence report on siponimod for treating secondary progressive multiple sclerosis
14 March 2019 - Public comment period now open until 10 April 2019; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 14 Mar 2019
An EU wide approach to HTA: an irrelevant development or an opportunity not to be missed?
14 March 2019 - An EU-wide cooperation on HTA has been proposed recently by the European Commission, focusing on relative effectiveness ...
Posted by Michael Wonder on 12 Mar 2019
Institute for Clinical and Economic Review publishes white paper on alternative models for pharmaceutical rebates
12 March 2019 - Paper explores how reforming or eliminating rebates may affect drug pricing, patient access, and incentives for future ...
Posted by Michael Wonder on 12 Mar 2019
NICE u-turn backs use of Darzalex combo for myeloma relapse
12 March 2019 - Myeloma patients in England are set to gain NHS access to a new second-line treatment combination ...
Posted by Michael Wonder on 12 Mar 2019
Overview of cost-effectiveness analysis
11 March 2019 - Health care decision makers, including patients, clinicians, hospitals, private health systems, and public payers (eg, Medicare), are ...
Posted by Michael Wonder on 12 Mar 2019
SMC says ‘no’ to Novartis’ Kymriah for adults with lymphoma
11 March 2019 - Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS ...
Posted by Michael Wonder on 11 Mar 2019
SMC - March 2019 decisions
11 March 2019 - The Scottish Medicines Consortium has today published advice accepting two new medicines. ...
Posted by Michael Wonder on 11 Mar 2019
NICE nod for Almirall's Ilumetri, UCB's Cimzia
11 March 2019 - The NICE has recommended Almirall's Ilumetri and UCB's Cimzia as a treatment options for severe plaque ...